Chikungunya virus is an alphavirus of the Togaviridae family. It is transmitted to human by the bites of infected female Aedes mosquitoes.

Chikungunya disease affects all age groups and causes fever, severe joint pain, muscle pain, headache, nausea, fatigue and rash. Joint pain is often debilitating and can persist during months or years.

Firstly identified in Tanzania in 1952, this pathogen re-emerged over the last two decades. In 2004, Chikungunya virus began to spread quickly, causing large-scale outbreaks in the southern Indian Ocean, parts of South America and the Caribbean. It continues to be a significant pathogen in Southeast Asia and India. The total number of cases has been estimated at over 3 millions.

Chikungunya virus has no preventative vaccine or treatments approved for use. As the climate warms, the epidemic risks are amplified which poses significant challenges, especially in developing countries.


Ciloa develops a virus-free and adjuvant-free Chikungunya vaccine :

  • No need of viruses (attenuated or inactivated), nor viral pseudo-particles
  • No need of artificial adjuvants, thanks to the natural adjuvant properties of exosomes
  • Easy and rapid implementation on Ciloa exosome platform of a new antigen in the event of a pandemic.